A big fight could be brewing over Obamacare's risk-corridor program. Insurers are relying on the program to protect them from major losses if their exchange customers end up being sicker and more costly than anticipated. But Republicans—most notably Sen. Marco Rubio (R-Fla.), a likely 2016...
A second potential blockbuster drug from Gilead Sciences to treat hepatitis C has been approved by the FDA. But at a cost of nearly $100,000 for a full course of treatment, it is certain to spark further debate over the pricing of specialty drugs.
Insurance industry officials will gather in Washington this week to discuss the biggest political, legal, legislative and regulatory issues their companies face at the local level.
On the eve of the 2015 open enrollment period for Medicare beneficiaries, insurance leaders will gather in Washington to discuss public healthcare programs.
Allowing cheaper health plans designed to cover just half of medical costs to be sold on the exchanges would result in 350,000 additional individuals enrolling in coverage in the next decade, according to an analysis by Avalere Health.
Nearly 17.4 million Americans participate in health savings account-eligible insurance plans, a decade after Congress authorized the creation of health savings accounts, according to results of a census released this week by industry trade group America's Health Insurance Plans.
Insurers are pushing the government to provide financial assistance to people buying what are commonly referred to as catastrophic health plans.
State-based and federally facilitated exchanges are required by the reform law to provide advanced premium tax credits and cost-sharing reductions to low-income plan enrollees. However, a study out this week from consultancy Avalere Health found that insurers' latitude in meeting these requirements...
The Veterans Affairs Department is an example of single-payer, government-provided healthcare.
The staggering cost of Sovaldi, the $1,000-a-pill treatment for hepatitis C, is prompting serious discussions among healthcare leaders about the price tags of potentially life-saving specialty drugs and whether the government should regulate those prices.
Federal officials are renewing strong warnings to hospitals and drug companies not to use charities as fronts to illegally funnel money to patients.
The steep cost of Sovaldi—Gilead Sciences' $1,000-per-pill treatment for hepatitis C—is prompting wide-ranging discussions about the cost of drugs and whether the government should take more steps to regulate the cost of potentially life-saving treatments.